Actively Recruiting
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
Led by Mclean Hospital · Updated on 2025-10-21
228
Participants Needed
1
Research Sites
269 weeks
Total Duration
On this page
Sponsors
M
Mclean Hospital
Lead Sponsor
N
National Institute of Mental Health (NIMH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
CONDITIONS
Official Title
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All genders, races, and ethnic origins, aged between 18 and 45
- Able to provide written informed consent and fluent in English
- Right-handed
- No psychotropic medications taken for at least 2 weeks
- Owns a smartphone (iPhone or Android) for ecological momentary assessment
- For Remitted MDD group: history of MDD as defined by DSM-5 and no anxiety disorder in past two months
- For Current MDD group: presence of MDD as defined by DSM-5 and no anxiety disorder in past two months
You will not qualify if you...
- Suicidal ideation unsafe for outpatient treatment
- Pregnant women or women of childbearing potential not using medically accepted contraception
- Serious or unstable medical illnesses including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic diseases
- History of seizure disorder
- Psychiatric illnesses other than depression or anxiety disorders (for Current and Remitted MDD groups)
- History of substance or alcohol use disorder except mild cases resolved over 12 months ago
- History of cocaine, stimulant, or dopaminergic drug use
- Diagnosis of dementia or Mini Mental State Examination score below 26
- Presence of mood congruent or incongruent psychotic features
- Current use of other psychotropic drugs
- Clinical or laboratory hypothyroidism
- Lifetime history of electroconvulsive therapy
- Failure to meet MRI safety requirements
- Abnormal ECG or lab results
- Contraindications for arterial line placement (e.g., abnormal Allen test, Raynaud's syndrome, anemia, bleeding disorders, fainting from blood draws)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
McLean Hospital
Belmont, Massachusetts, United States, 02478
Actively Recruiting
Research Team
T
Tracy Lam, BS
CONTACT
D
David Crowley, ALM
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here